Refine
Year of publication
- 2016 (332) (remove)
Document Type
- Article (290)
- Doctoral Thesis (17)
- Part of Periodical (13)
- Book (5)
- Contribution to a Periodical (3)
- Preprint (2)
- Conference Proceeding (1)
- Review (1)
Has Fulltext
- yes (332) (remove)
Is part of the Bibliography
- no (332)
Keywords
Institute
- Medizin (332) (remove)
A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21~22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with greater than or equal to4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21~22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.
DNA methylation is a major regulatory process of gene transcription, and aberrant DNA methylation is associated with various diseases including cancer. Many compounds have been reported to modify DNA methylation states. Despite increasing interest in the clinical application of drugs with epigenetic effects, and the use of diagnostic markers for genome-wide hypomethylation in cancer, large-scale screening systems to measure the effects of drugs on DNA methylation are limited. In this study, we improved the previously established fluorescence polarization-based global DNA methylation assay so that it is more suitable for application to human genomic DNA. Our methyl-sensitive fluorescence polarization (MSFP) assay was highly repeatable (inter-assay coefficient of variation = 1.5%) and accurate (r2 = 0.99). According to signal linearity, only 50–80 ng human genomic DNA per reaction was necessary for the 384-well format. MSFP is a simple, rapid approach as all biochemical reactions and final detection can be performed in one well in a 384-well plate without purification steps in less than 3.5 hours. Furthermore, we demonstrated a significant correlation between MSFP and the LINE-1 pyrosequencing assay, a widely used global DNA methylation assay. MSFP can be applied for the pre-screening of compounds that influence global DNA methylation states and also for the diagnosis of certain types of cancer.
The mitochondrial cascade hypothesis of dementia assumes mitochondrial dysfunction leading to reduced energy supply, impaired neuroplasticity, and finally cell death as one major pathomechanism underlying the continuum from brain aging over mild cognitive impairment to initial and advanced late onset Alzheimer's disease. Accordingly, improving mitochondrial function has become an important strategy to treat the early stages of this continuum. The metabolic enhancer piracetam has been proposed as possible prototype for those compounds by increasing impaired mitochondrial function and related aspects like mechanisms of neuroplasticity. We here report that piracetam at therapeutically relevant concentrations improves neuritogenesis in the human cell line SH-SY5Y over conditions mirroring the whole spectrum of age-associated cognitive decline. These effects go parallel with improvement of impaired mitochondrial dynamics shifting back fission and fusion balance to the energetically more favorable fusion site. Impaired fission and fusion balance can also be induced by a reduction of the mitochondrial permeability transition pore (mPTP) function as atractyloside which indicates the mPTP has similar effects on mitochondrial dynamics. These changes are also reduced by piracetam. These findings suggest the mPTP as an important target for the beneficial effects of piracetam on mitochondrial function.
The general assumption that brain size differences are an adequate proxy for subtler differences in brain organization turned neurobiologists toward the question why some groups of mammals such as primates, elephants, and whales have such remarkably large brains. In this meta-analysis, an extensive sample of eutherian mammals (115 species distributed in 14 orders) provided data about several different biological traits and measures of brain size such as absolute brain mass (AB), relative brain mass (RB; quotient from AB and body mass), and encephalization quotient (EQ). These data were analyzed by established multivariate statistics without taking specific phylogenetic information into account. Species with high AB tend to (1) feed on protein-rich nutrition, (2) have a long lifespan, (3) delayed sexual maturity, and (4) long and rare pregnancies with small litter sizes. Animals with high RB usually have (1) a short life span, (2) reach sexual maturity early, and (3) have short and frequent gestations. Moreover, males of species with high RB also have few potential sexual partners. In contrast, animals with high EQs have (1) a high number of potential sexual partners, (2) delayed sexual maturity, and (3) rare gestations with small litter sizes. Based on these correlations, we conclude that Eutheria with either high AB or high EQ occupy positions at the top of the network of food chains (high trophic levels). Eutheria of low trophic levels can develop a high RB only if they have small body masses.
Background: Ovarian cancer is mostly associated with pathologically regulated permeability of peritoneal vessels, leading to ascites. Here, we investigated the molecular regulation of endothelial permeability by the vascular endothelial growth factor (VEGF) and both tight and adherens junction proteins (VE-cadherin and claudin 5) with regards to the tumor biology of different ovarian cancer types.
Methods: Serum and ascites samples before and after surgery, as well as peritoneal biopsies of 68 ovarian cancer patients and 20 healthy controls were collected. In serum and ascites VEGF protein was measured by ELISA. In peritoneal biopsies co-localization of VE-cadherin and claudin 5 was investigated using immunohistochemical dual staining. In addition, the gene expression of VE-cadherin and claudin 5 was quantified by Real-time PCR. Differences in VEGF levels, VE-cadherin and claudin 5 gene expression were analyzed in relation to various tumor characteristics (tumor stage, grading, histological subtypes, resection status after surgery) and then compared to controls. Furthermore, human primary ovarian cancer cells were co-cultured with human umbilical vein endothelial cells (HUVEC) and changes in VE-cadherin and claudin 5 were investigated after VEGF inhibition.
Results: VEGF was significantly increased in tumor patients in comparison to controls and accumulates in ascites. The highest VEGF levels were found in patients diagnosed with advanced tumor stages, with tumors of poor differentiation, or in the group of solid / cystic-solid tumors. Patients with residual tumor after operation showed significantly higher levels of VEGF both before and after surgery as compared to tumor-free resected patients. Results of an immunohistochemical double-staining experiment indicated co-localization of VE-cadherin and claudin 5 in the peritoneal vasculature. Compared to controls, expression of VE-cadherin and claudin 5 was significantly suppressed in peritoneal vessels of tumor patients, but there were no significant differences regarding VE-cadherin and claudin 5 expression in relation to different tumor characteristics. A significant positive correlation was found between VE-cadherin and claudin 5 expression. VEGF inhibition in vitro was associated with significant increase in VE-cadherin and claudin 5.
Conclusions: Our results indicate that increased peritoneal permeability in ovarian cancer is due to down-regulation of adhesion proteins via tumor derived VEGF. Advanced ovarian cancer with aggressive tumor biology may be associated with early dysregulation of vascular permeability leading to ascites. These patients may benefit from therapeutic VEGF inhibition.
Neurological diseases associated with neuronal death are also accompanied by axonal denervation of connected brain regions. In these areas, denervation leads to a decrease in afferent drive, which may in turn trigger active central nervous system (CNS) circuitry rearrangement. This rewiring process is important therapeutically, since it can partially recover functions and can be further enhanced using modern rehabilitation strategies. Nevertheless, the cellular mechanisms of brain rewiring are not fully understood. We recently reported a mechanism by which neurons remodel their local connectivity under conditions of network-perturbance: hippocampal pyramidal cells can extend spine head protrusions (SHPs), which reach out toward neighboring terminals and form new synapses. Since this form of activity-dependent rewiring is observed only on some spines, we investigated the required conditions. We speculated, that the actin-associated protein synaptopodin, which is involved in several synaptic plasticity mechanisms, could play a role in the formation and/or stabilization of SHPs. Using hippocampal slice cultures, we found that ~70 % of spines with protrusions in CA1 pyramidal neurons contained synaptopodin. Analysis of synaptopodin-deficient neurons revealed that synaptopodin is required for the stability but not the formation of SHPs. The effects of synaptopodin could be linked to its role in Ca(2+) homeostasis, since spines with protrusions often contained ryanodine receptors and synaptopodin. Furthermore, disrupting Ca(2+) signaling shortened protrusion lifetime. By transgenically reintroducing synaptopodin on a synaptopodin-deficient background, SHP stability could be rescued. Overall, we show that synaptopodin increases the stability of SHPs, and could potentially modulate the rewiring of microcircuitries by making synaptic reorganization more efficient.
Introduction: Neuronal death and subsequent denervation of target areas are hallmarks of many neurological disorders. Denervated neurons lose part of their dendritic tree, and are considered "atrophic", i.e. pathologically altered and damaged. The functional consequences of this phenomenon are poorly understood.
Results: Using computational modelling of 3D-reconstructed granule cells we show that denervation-induced dendritic atrophy also subserves homeostatic functions: By shortening their dendritic tree, granule cells compensate for the loss of inputs by a precise adjustment of excitability. As a consequence, surviving afferents are able to activate the cells, thereby allowing information to flow again through the denervated area. In addition, action potentials backpropagating from the soma to the synapses are enhanced specifically in reorganized portions of the dendritic arbor, resulting in their increased synaptic plasticity. These two observations generalize to any given dendritic tree undergoing structural changes.
Conclusions: Structural homeostatic plasticity, i.e. homeostatic dendritic remodeling, is operating in long-term denervated neurons to achieve functional homeostasis.
In etwa 40% der Fälle erleiden Patienten bei einem Polytrauma eine Verletzung des Thorax. Diese Patienten haben im Verlau ein erhöhtes Pneumonierisiko, eine längere Beatmungs-, Intensiv- und Krankenhausverweildauer sowie ein erhöhtes Letalitätsrisiko. Um eine optimierte Versorgung dieser Patienten zu erreichen wurde seit 2003 im Universitätsklinikum Frankfurt ein standardisiertes Behandlungsverfahren durchgeführt und über die Jahre weiterentwickelt. Grundlage dieses Konzepts ist die Behandlung des Patienten mittels kinetischer Therapie im Rotorest®Bett sowie den drei Kern-Maßnahmen: Beatmung mit einem PEEP von 15mbar, frühzeitige assistierte Spontanatmung und frühzeitige enterale Ernährung. Ziel der Arbeit war die Weiterentwicklung des Behandlungsstandards wissenschaftlich unter besonderem Fokus auf die Entwicklung einer Pneumonie aufzuarbeiten. Das Konzept sah 2003 eine Beatmung, mit einem an die Oxygenierung adaptierten PEEP vor. Die Dauer der Therapie im Rotorest®Bett wurde nach Klinik entschieden. 2006 wurde standardmäßig die Therapie im Rotorest®Bett für mindestens 72h mit einem PEEP von 15mbar durchgeführt. Eine assistierte Beatmungsform sollte zeitnah etabliert werden. Im Jahr 2009, wurde das Behandlungsschema verkürzt, die Therapiedauer mit einem PEEP von 15mbar wurde auf 40 bis 48 Stunden reduziert sowie der PEEP danach initial um 4mbar reduziert. Im Anschluss erfolgte alle 8 Stunden eine weitere Reduktion des PEEP um 2mbar. Weiterhin wurde in diesem Zeitraum auf eine Antiinfektivaprophylaxe verzichtet. 108 Patienten (61,7%; ISS 37±13 Punkte) konnten in diese retrospektive Studie eingeschlossen werden. 38,3% der Patienten mussten ausgeschlossen werden, einerseits auf Grund fehlender Krankenakten oder anderseits auf Grund des Beginns der Therapie im RotoRest®Bett erst nach >48h. Durch die Anpassung des Therapiestandards über die Jahre reduzierte sich die Beatmungszeit von 17±15 Tage auf 8±8 Tage (p<0,001), die Verweildauer auf ITS von 17±9 auf 10±9 Tage (p<0,001), während die Krankenhausverweildauer unverändert blieb. Dies war begleitet von einer Reduktion der Therapiedauer im Rotorest®Bett von im Median 5 auf 3 Tage (p=0,017) sowie einer Reduktion des Anteils an Patienten mit mandatorischer Beatmung in den ersten drei Behandlungstagen von 87% (95% CI 78-96%) im Jahr 2003 auf 38,6% (95% CI 29-49%) im Jahr 2009. Die Rate an Pneumonien konnte von 25% in 2003 über 37% in 2006 auf 17% in 2009 gesenkt werden, der Unterschied war jedoch nicht signifikant. Das Risiko zu versterben war bei Entwicklung einer Pneumonie signifikant erhöht (24% vs. 4,5%, p=0,006). In der univariaten Analyse waren relevante Faktoren für die Entwicklung einer Pneumonie ein höheres Alter der Patienten (48 Jahre vs. 36 Jahre; p = 0,018), die zunehmende Höhe des Beatmungsspitzendruckes (p<0,01) sowie der Hämoglobinwert bei Aufnahme (Rs -0,28; p=0,004). Umgekehrt war eine Transfusion von Blutprodukten am ersten Behandlungstag mit einem erhöhten Pneumonierisiko verbunden (p<0,05), dies galt auch für die Verabreichung der einzelnen Komponenten, EKs (p=0,027), FFP (p=0,037) sowie von TKs (p=0,046). Keine signifikante Korrelation zur Entwicklung einer Pneumonie hatte die Verletzungsschwere (ISS) sowie die Höhe des PEEP oder der Grad der Oxygenierungsstörung (paO2/FiO2) in den ersten fünf Behandlungstagen. In der multivariaten Analyse, mit der Entwicklung einer Pneumonie als abhängigen Faktor, adjustiert auf ISS und Alter der Patienten zeigte sich als unabhängige Risikofaktoren die Gabe von EKs (OR 3,646 95%CI 1,074-12,383), die Ernährung mit >5000kcal in den ersten fünf Behandlungstagen (OR 3,219 95%CI 1,033-10,034) sowie die Höhe des Beatmungsspitzendruckes (OR 1,135 95%CI 1,010-1,275).
In Zusammenschau war ein primärer Erfolg des Konzeptes, dass kein Patient im Verlauf ein moderates oder schweres ARDS entwickelt hat. Es konnte durch die Anpassung des Behandlungsstandards sowohl die Beatmungszeit als auch die Verweildauer auf der ITS signifikant reduziert werden. Auch die Pneumonierate konnte nach einem Anstieg im Jahr 2006 bis 2009 deutlich reduziert werden. Als Risikofaktoren für die Entwicklung einer Pneumonie zeigten sich aus der Literatur bekannte Parameter wie das Alter der Patienten und die Invasivität der Beatmung sowie die Transfusion von Blutprodukten. In der multivariaten Analyse bestätigte sich dies für die Gabe von EKs, die Invasivität der Beatmung sowie der Ernährung mit kumulativ > 5000 kcal in den ersten fünf Tagen.
Patienten, die mit dem in dieser Arbeit beschrieben Protokoll behandelt wurden, zeigten aber kein signifikant erhöhtes Pneumonierisiko in Abhängigkeit zur Verletzungsschwere als Polytrauma (ISS) oder zum Grad der Oxygenierungsstörung in den ersten Tagen.
19(S)-hydroxy-eicosatetraenoic acid (19(S)-HETE) belongs to a family of arachidonic acid metabolites produced by cytochrome P450 enzymes, which play critical roles in the regulation of cardiovascular, renal and pulmonary functions. Although it has been known for a long time that 19(S)-HETE has vascular effects, its mechanism of action has remained unclear. In this study we show that 19(S)-HETE induces cAMP accumulation in the human megakaryoblastic leukemia cell line MEG-01. This effect was concentration-dependent with an EC50 of 520 nM, insensitive to pharmacological inhibition of COX-1/2 and required the expression of the G-protein Gs. Systematic siRNA-mediated knock-down of each G-protein coupled receptor (GPCR) expressed in MEG-01 followed by functional analysis identified the prostacyclin receptor (IP) as the mediator of the effects of 19(S)-HETE, and the heterologously expressed IP receptor was also activated by 19(S)-HETE in a concentration-dependent manner with an EC50 of 567 nM. Pretreatment of isolated murine platelets with 19(S)-HETE blocked thrombin-induced platelets aggregation, an effect not seen in platelets from mice lacking the IP receptor. Furthermore, 19(S)-HETE was able to relax mouse mesenteric artery- and thoracic aorta-derived vessel segments. While pharmacological inhibition of COX-1/2 enzymes had no effect on the vasodilatory activity of 19(S)-HETE these effects were not observed in vessels from mice lacking the IP receptor. These results identify a novel mechanism of action for the CYP450-dependent arachidonic acid metabolite 19(S)-HETE and point to the existence of a broader spectrum of naturally occurring prostanoid receptor agonists.
Objectives: Assessment of the clinical severity of Fabry disease (FD), an X-linked, rare, progressive disorder based on a genetic defect in alpha-galactosidase is challenging, especially regarding cardiac involvement. The aim of the study was to evaluate the diagnostic value of cardiac troponin I (cTnI) in discriminating FD patients with cardiac involvement in a large FD patient cohort.
Methods: cTnI levels were measured with a contemporary sensitive assay in plasma samples taken routinely from FD patients. The assay was calibrated to measure cTnI levels ≥0.01 ng/ml. Elevated cTnI values (cut-off ≥0.04 ng/ml) were correlated with clinical data.
Results: cTnI was assessed in 62 FD patients (median age: 47 years, males: 36%). Elevated cTnI levels were detected in 23 (37%) patients. Patients with a cTnI elevation were older (median 55 years versus 36 years, p<0.001). Elevated cTnI levels were associated with the presence of a LVH (16/23 versus 1/39; OR 65.81, CI: 6.747–641.859; p<0.001). In almost all patients with a left ventricular hypertrophy (LVH) elevated cTnI levels were detected (16/17, 94%). Absolute cTnI levels in patients with LVH were higher than in those without (median 0.23 ng/ml versus 0.02 ng/ml; p<0.001). A cTnI level <0.04ng/ml had a high negative predictive value regarding the presence of a LVH (38/39, 97%). In a control group of non-FD patients (n = 17) with LVH (due to hypertension) none showed cTnI levels ≥0.01 ng/ml.
Conclusions: Elevated cTnI levels are common in FD patients, reflecting cardiac involvement. FD patients might benefit from a continuous cTnI monitoring.